On 11 August, Curaleaf announced its intention to launch a takeover bid for Aurora Cannabis. US$4.00 per share, made up of 0.3463 Curaleaf shares plus US$0.75 in cash, capped at US$5.00. That is a 45 percent premium to the 30 day volume weighted average price and, the more interesting number, a 110 percent premium once you strip out the cash sitting on Aurora’s balance sheet. Total consideration is around US$272 million. Aurora formed a special committee of independent directors the same day and disputes the claim that it refused to engage.
The press release talks about an end to end supply chain and a global leader across 17 countries. That is the packaging. The content is simpler, and Boris Jordan said it out loud himself a day later. Curaleaf is buying market share in European medical cannabis because that share cannot be built. Certainly not inside the window Curaleaf has set for itself.
The number that explains the deal
Curaleaf currently owns roughly 20 percent of the flower it sells outside the United States. A few days ago, management told the market it wants to be at 50 to 75 percent within six to twelve months. That is not a sourcing preference, it is emergency surgery. The CEO called supply chain the single biggest problem in the international business: failed product, late delivery to pharmacies, and a cash conversion cycle running at around 120 days that verticalising is supposed to push below 60.
The stated path there is expanding its own facilities in Portugal and Canada, plus opportunistic acquisitions where the pricing is right. But the jump from 20 to 75 percent in twelve months simply cannot be done organically. Anyone serious about that target has to buy. And there is exactly one asset on the board in the right size range.
Jordan says it himself on the podcast
On 12 August, Jordan sat down with Shadd Dales on the Trade To Black podcast, for the second time in a week, this time in a special broadcast on the offer. And he said out loud what the press release only implies. Curaleaf brings the largest international distribution platform, but it has been short on premium EU-GMP flower. That is precisely what Aurora delivers, with more than 50 tonnes of annual EU-GMP cultivation and manufacturing capacity plus the recently acquired Safari Flower Company, ready to plug into Curaleaf’s network across Germany, the UK and Poland.
Let that 50 tonne figure sit for a moment. Canada shipped 93 tonnes to Germany in total last year. So this is not a portfolio addition. It is a meaningful share of the entire Canadian supply base serving the largest European market.
Jordan also made two things clear that matter more for context than any valuation argument. First, he has given the Aurora board until early next week before he takes a formal bid straight to shareholders. Second, this is neither his first nor his last deal. In the 6 August episode, five days before the announcement, he had already argued that the industry is primed for consolidation, speculated openly about a merger among the top five operators, and said he would happily hand over the CEO reins for the right deal. In hindsight, that was not market commentary. It was a heads up.
The European chain is nearly complete, only volume is missing
Looking at the existing structure makes it clear why now and why Aurora. Curaleaf today names three locations with EU-GMP certified facilities: Portugal, Spain and Canada. Portugal is the real European anchor. There is a cultivation site in Alcochete, which came out of Terra Verde, and since 2023 the acquired assets of the Clever Leaves EU-GMP processing unit in the same region. That deal was justified at the time precisely as a way to bring cultivation and processing together in Portugal and accelerate the supply of EU-GMP flower to European markets, Germany and the UK above all.
At the other end of the chain, Curaleaf completed the acquisition of the remaining 45 percent of Four 20 Pharma in April this year, taking full control of an EU-GMP and GDP licensed distributor in the largest European market.
That closes the chain at both ends. Certified processing in the south, licensed distribution in Germany, and pharmacies, clinics and patient access in between. What is missing is volume. And that is exactly what Curaleaf is buying now.
A footnote with some irony: Aurora was once active in Portugal itself and left the country in 2020 during a restructuring. Six years on, it would become the supplier to a Portuguese platform that a competitor built in the meantime.
The Cannara contract shows the bottleneck in its purest form
If you want to understand the structural issue, do not read the takeover announcement. Read the supply agreement from 14 July. Curaleaf International signed a long term agreement with Cannara Biotech of Quebec for bulk flower, potentially worth up to C$21 million, effective 1 August. Cannara activated two additional cultivation zones at Valleyfield for it.
The decisive paragraph sits further down. Curaleaf will support Cannara in obtaining EU-GMP certification for its own processing centre. Until that lands, every single gram supplied under the agreement is dried and processed at Curaleaf’s already certified Canadian facility before it can be released to a European patient.
The supplier had the plants. The buyer had the certificate. That is the entire bottleneck, visible in a single transaction. Four weeks later, the same bottleneck, two orders of magnitude larger, is being addressed with a takeover bid.
Why American operators cannot solve this at home
Germany imported just over 200 tonnes of medical cannabis flower last year, against roughly 72 tonnes the year before. 93 tonnes came from Canada. Around two tonnes were grown in Germany itself.
US operators cannot fill that gap from their own production right now, and the reason is sequencing rather than ambition. Medical cannabis moved to Schedule III in April, and the adult use hearing process concluded in July. The operator furthest down this road puts US export at roughly twelve months out and places it last on its own priority list. That estimate is optimistic by a wide margin. Three years is the realistic figure, for three reasons rescheduling does not touch.
First, almost no US cultivation was built to GACP or EU-GMP specification, because it was built for state markets that never asked for it. For most of the cohort that means a retrofit or a new build, not a paperwork exercise. Second, certification needs operating history and not just a compliant building. Batch records and demonstrated process control have to exist before an inspector will engage. Third, the inspection is its own queue, currently long enough that certification alone runs twelve to eighteen months. It is the same queue every Canadian applicant is already sitting in.
Canada’s advantage here is not regulatory favour. It is a decade of inspections that already happened.
What Aurora actually brings to the table
In the quarter to the end of June, Aurora reported C$67.6 million in net revenue, C$43 million of it in international medical, up 17 percent and driven mainly by Germany. 64 percent of total revenue now comes from outside Canada, against 50 percent a year earlier. Adjusted gross margin sits at 58 percent, and there is close to C$150 million in cash with no debt. Safari Flower was acquired in April, and its Ontario facility received a three year EU-GMP certification in July.
Over the same period Curaleaf posted US$340 million in revenue, US$51 million of it international, up 26 percent. Together the two would have more than US$1.5 billion in trailing twelve month revenue and around US$350 million in adjusted EBITDA. Curaleaf expects at least US$40 million in annual savings, partly from running Aurora’s business on its own leaner overhead, partly from optimising cultivation capacity and introducing its own genetics into Aurora’s facilities.
So what Curaleaf is buying is not square footage. It is certified capacity, a patient base, and above all operating history that cannot be ordered anywhere.
The price, and who actually holds the leverage
Strip out Aurora’s cash and Curaleaf is paying surprisingly little for the operating business. That is exactly what makes the US$5.00 cap awkward. Aurora points out that the cap sits below its own share price on 18 December 2025. TD Cowen considers the offer too low and does not see long term intrinsic value reflected in it.
The timing asymmetry is worth noting. Curaleaf has committed itself to six to twelve months and given the board a deadline of a few days. Aurora sits on a lead that a US competitor closes in three years at the earliest. The party under time pressure is not the target. That asymmetry belongs in the price, and a special committee doing its job will calculate exactly that. Once the offer formally launches it stays open for 105 days, unless Curaleaf extends, accelerates or withdraws it. Time enough for a counterbid from someone running the same maths.
A side note with symbolic value: hostile takeover attempts are extremely rare in this industry, and one of the few came from Aurora itself, when it reached for CanniMed unsolicited in 2017. Nine years on, Aurora is on the other side of the table.
What this means for the German market
For pharmacies, importers and distributors here, this is not a North American footnote. One number from our pharmacy data shows how relevant Aurora already is: 7.49 euros per gram, averaged across all Aurora genetics in the German market. That is not the price of a niche supplier. That is a volume player sitting right in the middle of price formation, in a market moving 200 tonnes. Combine that position with the second largest international distribution platform and you are not just changing a balance sheet, you are moving the line German prices anchor to.
A merged supplier of that size shifts the negotiating position on the supply side, in a market where wholesale prices have been under pressure for months. Anyone assuming flower is freely substitutable should look at how many of the Canadian facilities currently shipping are actually certified, export capable, and not already contractually committed. That list is shorter than the market is pricing.
And that is the real lesson from this week. The pool of Canadian capacity that is already EU-GMP certified, already exporting, and not already locked up is being repriced by buyers who need it inside a year and cannot replicate it for three. Jordan has said this will not be his only deal. That is the actual news for everyone sitting on the sell side who has not worked it out yet.
Anyone valuing a Canadian cultivation asset off domestic wholesale economics today is pricing it for the wrong buyer.
More data? Happy to share, write to falk@cannabis-startups.com
